120 related articles for article (PubMed ID: 26601880)
1. Inverse association of HbA1c with faecal elastase 1 in people without diabetes.
Rathmann W; Haastert B; Oscarsson J; Berglind N; Wareham NJ
Pancreatology; 2015; 15(6):620-5. PubMed ID: 26601880
[TBL] [Abstract][Full Text] [Related]
2. Association of faecal elastase 1 with non-fasting triglycerides in type 2 diabetes.
Rathmann W; Haastert B; Oscarsson J; Berglind N; Lindkvist B; Wareham NJ
Pancreatology; 2016; 16(4):563-9. PubMed ID: 27086060
[TBL] [Abstract][Full Text] [Related]
3. Low faecal elastase 1 concentrations in type 2 diabetes mellitus.
Rathmann W; Haastert B; Icks A; Giani G; Hennings S; Mitchell J; Curran S; Wareham NJ
Scand J Gastroenterol; 2001 Oct; 36(10):1056-61. PubMed ID: 11589378
[TBL] [Abstract][Full Text] [Related]
4. New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer.
Lu Y; García Rodríguez LA; Malgerud L; González-Pérez A; Martín-Pérez M; Lagergren J; Bexelius TS
Br J Cancer; 2015 Dec; 113(11):1607-14. PubMed ID: 26575601
[TBL] [Abstract][Full Text] [Related]
5. Distinct trajectories of HbA
Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
[TBL] [Abstract][Full Text] [Related]
6. Use of snacks in insulin-treated people with diabetes mellitus and association with HbA1c , weight and quality of life: a cross sectional study.
Heller T; Kloos C; Keßler D; Müller N; Thierbach R; Wolf G; Müller UA
Diabet Med; 2015 Mar; 32(3):353-8. PubMed ID: 25345907
[TBL] [Abstract][Full Text] [Related]
7. Association between hemoglobin A1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998.
Paprott R; Schaffrath Rosario A; Busch MA; Du Y; Thiele S; Scheidt-Nave C; Heidemann C
Diabetes Care; 2015 Feb; 38(2):249-56. PubMed ID: 25414153
[TBL] [Abstract][Full Text] [Related]
8. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
9. Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses.
Rathmann W; Pscherer S; Konrad M; Kostev K
Prim Care Diabetes; 2016 Feb; 10(1):36-40. PubMed ID: 25937183
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control.
Terzin V; Várkonyi T; Szabolcs A; Lengyel C; Takács T; Zsóri G; Stájer A; Palkó A; Wittmann T; Pálinkás A; Czakó L
Pancreatology; 2014; 14(5):356-60. PubMed ID: 25278304
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.
Hanefeld M; Fleischmann H; Schiffhorst G; Bramlage P
Diabetes Technol Ther; 2014 Apr; 16(4):241-6. PubMed ID: 24229089
[TBL] [Abstract][Full Text] [Related]
12. Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies.
Hambling CE; Seidu SI; Davies MJ; Khunti K
Diabet Med; 2017 Sep; 34(9):1219-1227. PubMed ID: 28498634
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of exocrine pancreatic insufficiency in patients with diabetes mellitus.
Vujasinovic M; Zaletel J; Tepes B; Popic B; Makuc J; Epsek Lenart M; Predikaka M; Rudolf S
Pancreatology; 2013; 13(4):343-6. PubMed ID: 23890131
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System.
Mast MR; Walraven I; Hoekstra T; Jansen AP; van der Heijden AA; Elders PJ; Heine RJ; Dekker JM; Nijpels G; Hugtenburg JG
Diabet Med; 2016 Jun; 33(6):794-802. PubMed ID: 26946450
[TBL] [Abstract][Full Text] [Related]
15. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
16. Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a prospective multi-centre trial.
Ewald N; Bretzel RG; Fantus IG; Hollenhorst M; Kloer HU; Hardt PD;
Diabetes Metab Res Rev; 2007 Jul; 23(5):386-91. PubMed ID: 17103488
[TBL] [Abstract][Full Text] [Related]
17. Intensification patterns and the probability of HbA
Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman JM; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
Diabet Med; 2020 Jul; 37(7):1114-1124. PubMed ID: 30653705
[TBL] [Abstract][Full Text] [Related]
18. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change.
Hirst JA; Stevens RJ; Farmer AJ
PLoS One; 2014; 9(3):e92458. PubMed ID: 24667212
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
20. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
